The bottom line: Clinician attitudes can shape patient access to psychedelic assisted psychotherapy as much as the evidence base, particularly in culturally diverse healthcare settings. This study shows that even a one hour, culturally informed training can increase knowledge, reduce safety concerns, and improve willingness to refer patients, which has direct implications for mental health access and well being. For healthcare practice and public policy, investing in brief, targeted education may be a practical way to support more equitable and culturally responsive adoption of emerging treatments.
For many patients with depression, trauma, or treatment resistant mental health issues, access to emerging therapies depends not only on scientific evidence but also on whether clinicians are willing to engage with them. New research suggests that even brief education can shift professional attitudes towards psychedelic assisted psychotherapy, an area of mental health care that remains controversial despite growing interest.
A study published in Psychreg Journal of Psychology examined how Chinese American mental health providers responded to a one hour online educational programme focused on psychedelic assisted psychotherapy. The research addressed a notable gap in the literature, as Asian American clinicians have been largely absent from previous studies, even though cultural factors strongly influence how mental health treatments are viewed and delivered.
Huiqiong Deng, MD, PhD, clinical associate professor at Stanford University, said the study was designed to explore how culturally shaped perceptions affect clinical openness to psychedelic therapies. She explained: “The primary goal for this study was to assess and address a significant gap in the existing literature regarding the attitudes of Asian American mental health providers towards psychedelic assisted psychotherapy (PAP). While there is a renaissance of interest in psychedelic therapies in the United States, most clinical studies have predominantly enrolled White participants.”
Psychedelic assisted psychotherapy involves the supervised use of substances such as psilocybin, MDMA, or ketamine alongside structured psychological support. Interest in these approaches has increased rapidly in recent years, particularly for conditions such as post traumatic stress disorder and severe depression. However, concerns remain about cultural relevance and trust, especially in communities where psychoactive substances carry strong stigma.
Dr Deng noted that these concerns are often rooted in cultural values rather than a lack of clinical curiosity. She said, “Asian cultures often hold conservative views towards psychoactive substances due to stigma, collectivism, filial piety, and associations with recreational misuse.” The study sought to determine whether targeted education could address these barriers.
Participants were recruited from an online peer support group of Chinese American mental health providers and invited to attend a one hour educational session covering the history, scientific evidence, clinical practice, safety considerations, and misuse concerns related to psychedelic assisted psychotherapy. Fourteen clinicians completed surveys before and after the session, allowing researchers to assess changes in attitudes.
Before the training, scepticism was common. Many participants viewed psychedelic treatments as unsafe or unsuitable for clinical practice and were reluctant to consider referrals or involvement. After the session, participants reported increased knowledge, greater openness to the therapy, and a higher willingness to refer patients. Concerns about safety and dependence declined, although apprehension about misuse remained.
Dr Deng said: “A one-hour online educational session covering the history, science, clinical practice, safety considerations, and misuse concerns of psychedelics meaningfully altered attitudes among a small sample of participants.” She added that education represents a modifiable factor in clinician decision making.
The study also identified practical barriers to wider adoption. Providers cited patient safety, financial cost, insurance limitations, stigma, and the level of responsibility placed on clinicians as ongoing challenges. These concerns help explain why many clinicians preferred referral rather than direct provision of psychedelic assisted psychotherapy.
Dr Deng emphasised the need for broader and more inclusive research. She said: “The study recommends larger, more representative samples with broader recruitment to enhance generalisability and minimise selection and recall bias.” She also highlighted calls for culturally tailored training and further research to determine whether changes in attitude lead to changes in clinical practice.
The findings suggest that brief, well-designed educational interventions can play a meaningful role in shaping clinician perspectives. Without culturally sensitive training and inclusive research, emerging mental health treatments risk remaining inaccessible to large segments of the population.
